New coverage looks at whether organized follow-up help can limit the weight that tends to come back once people come off GLP-1 drugs.
Recap by typeshit. Full story at Medscape.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
Doctors report two patients who developed perianal abscesses while on tirzepatide. A case report, not proof the drug caused them.
The bank sees room for another small guidance upgrade, but thinks investors will care more about where Novo goes next than about the quarter itself.
Loading…